# AHI lists Digital Health Check in Microsoft Azure Marketplace and joins Microsoft ISV Success Program

Highlights

- **AHI joins Microsoft ISV success, enabling access to more customers.**

- **AHI's Digital Health Check, a webcam or smartphone camera-based digital biomarker health risk assessment, now offered via Microsoft Azure Marketplace.**

- **Microsoft has over 10,000 partners globally across the health care sector.**

Perth, Western Australia, January 13, 2025 - Advanced Health Intelligence Ltd (ASX:AHI) ("Advanced Health Intelligence", "AHI", or "the Company") is pleased to announce that it has taken the first steps towards leveraging the Microsoft Marketplace to drive commercialisation of its digital health solutions. AHI has completed registration for the Microsoft ISV Success program as an AI Cloud Partner, gaining access to a range of benefits to support its commercial journey, and listed its Digital Health Check (DHC) solution as an offering in the Azure Marketplace.

An evolution of the Company's FaceScan offering, the DHC provides insights on an expanded range of health markers, via the web using a computer or smartphone in around two minutes. With the new listing in the Azure Marketplace, AHI is targeting companies looking to leverage this innovative technology as a tool to engage and support employees in proactively managing their health. Initially AHI will engage directly with companies interested in offering the DHC to their employees, providing bespoke integration support for delivery of health risk assessment and insights within customers' platforms.

Caption: AHI's Digital Health Check now listed on Microsoft Azure marketplace, available at https://azuremarketplace.microsoft.com/en-us/marketplace/apps/ahi.offer_dhc_contact_us

Over the course of 2025, AHI will be working with the Microsoft support team to transition its DHC into a Software as a Service offering that is fully transactable in the Azure Marketplace. This will provide Microsoft customers the advantage of being able to directly commission AHI services, eliminating the need for independent procurement and fast-tracking the period from commissioning to deployment.

Advanced Health Intelligence Ltd.
ACN 602 111 115
Postal Address: PO Box 190, South Perth WA 6951
Email: investors@ahi.tech

1

As an immediate next step, AHI is working on readiness for deployment as an embedded App on Microsoft Teams, expected by the end of the first quarter of 2025. This functionality will enable AHI to capture even greater value from the employer market while also expanding its use cases to additional sectors such as telehealth, for example enabling health risk assessments to be conducted digitally either during or in advance of consultations conducted using Microsoft Teams.

In 2021, Microsoft took a significant step in advancing artificial intelligence and cloud technology for its health care partners by acquiring Nuance Communications. This strategic move strengthened Microsoft's AI capabilities and brought an additional 10,000 health care customers into its ecosystem. These organisations, already committed to digitising their health care strategies as users of Nuance's industry-leading natural language processing (NLP) AI solutions, exemplify the growing demand for intelligent, cloud-based tools that enhance patient outcomes, streamline workflows, and empower health care providers globally.

With the addition of AHI solutions to the Microsoft Azure Marketplace, AHI's proprietary capabilities are now more easily accessible to these organisations. This integration aligns with Microsoft's vision of advancing health care innovation and underscores AHI's commitment to working closely with Microsoft and its team. Together, AHI aims to support these health care organisations with advanced risk assessment capabilities to enhance patient care, improve operational efficiencies, and drive the adoption of our transformative health technologies.

In the longer term, AHI will have the opportunity to meet commercial milestones and qualify for additional benefits such as co-selling opportunities with Microsoft sellers, marketing assistance and the use of customers' committed cloud budgets to fund its services to achieve an even faster adoption rate for AHI services.

Scott Montgomery, CEO of AHI commented:

"Becoming a partner to one of the world's largest companies unlocks an exceptional opportunity for AHI. This collaboration offers the potential to deliver digital health risk assessment to millions of Microsoft enterprise customers across APAC and globally.

"The entire company is energized by the potential to drive early intervention using insights from proactive health risk assessment, in conjunction with one of history's strongest technology brands, and we're proud of the impact that we could make together. Not only will this bring convenience to end users who can self-assess health risks almost any time, but it also rewards AHI shareholders with our technology deployed at scale. 2025 is shaping up to be a breakout year, and we're incredibly excited about what's ahead."

As companies progress through the Microsoft AI Cloud Partner program, products undergo a vetting process which includes review of the product's functionality, scalability and technical readiness for deployment, in addition to customer value, pricing and contracting models. AHI is looking forward to providing further updates throughout this journey.

AHI is working with the Microsoft team towards finalising the partnerships' first customer engagement. The listing is available at https://azuremarketplace.microsoft.com/en-us/marketplace/apps/ahi.offer_dhc_contact_us

This announcement has been approved by the Chairman and CEO of Advanced Health Intelligence Ltd.

For more information, contact:

Media: Laura Wilson	**Investors:** Scott Montgomery
Chief Marketing Officer	Chief Executive Officer
Advanced Health Intelligence Ltd	Advanced Health Intelligence Ltd
E: media@ahi.tech	E: investors@ahi.tech

Advanced Health Intelligence Ltd.
ACN 602 111 115
Postal Address: PO Box 190, South Perth WA 6951
Email: investors@ahi.tech

2

About Advanced Health Intelligence Ltd.

AHI offers cutting-edge, smart-phone-based health risk identification solutions that enable individuals to run their own comprehensive health assessments and risk stratification. Utilising smartphone sensor technology, individuals can efficiently conduct a single scan or a series of scans to identify established risk markers for various health conditions. The resulting data can then be shared with health care providers, insurers, employers, and government agencies, facilitating timely triage and appropriate care pathway allocation.

AHI's scientific research capability is dedicated to the development of advanced data capture techniques, optimising data input signal quality and continuous enhancement and validation of AHI's solutions through rigorous scientific processes. AHI has assembled a team of experts in machine learning, artificial intelligence, biomathematical modelling and systems biology, computer vision, clinical expertise, and medically trained data scientists to develop and deploy this cutting-edge risk assessment tool.

Over the past decade, AHI has been at the forefront of health-tech innovation, pioneering the use of smartphones in digital-first health care. Our journey began with the groundbreaking development of the world's first on-device body dimensioning capability.

Since then, we have continued to evolve and adapt our solutions to meet the dynamic needs of health systems players, who are dedicated to delivering high-quality patient care and early detection of escalating health conditions. AHI's patented technology has enabled us to push the boundaries of early detection through digital health care, offering a suite of modular solutions that are transforming the industry and offering earlier intervention opportunities.

Our comprehensive solutions encompass:

- Anthropometric and body composition analysis to identify obesity-related comorbidities, including diabetes risk stratification.

- Predictive modelling of blood biomarkers, (including HbA1C, HDL-C, LDL-C), and 10-year cardiovascular risk estimation.

- Facial photoplethysmography to assess vital signs non-invasively and provide risk stratification for cardiovascular disease.

- Device-derived dermatological image analysis for identifying over 588 skin conditions across 134 categories, including melanoma detection.

- Atrial Fibrillation technology enabling the detection of Atrial Fibrillation using a mobile device, allowing for early identification and monitoring of this common heart condition through a simple, non-invasive, and user-friendly smartphone-based solution.

AHI has developed digital biomarker driven triage solutions using only a smartphone or web browser. These solutions enable the identification of health risks across populations and can inform direction of individuals to appropriate care pathways for proactive health management. The technology provides cost-effective health risk assessment access to billions of smartphone users worldwide, empowering these individuals to take charge of their health journey and improving health outcomes globally.

For more information, please visit: www.ahi.tech.

Advanced Health Intelligence Ltd.
ACN 602 111 115
Postal Address: PO Box 190, South Perth WA 6951
Email: investors@ahi.tech

3